Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 6 6 6
ROE
(106.52%) 22.26% 53.10% 66.97%
ROA
(26.99%) 9.26% 21.91% 23.44%
ROIC
0.00% 47.09% 72.11% 134.59%
Return on Tangible Assets
110.55% 29.79% 62.15% 78.61%
Average Days of Receivables
211.67 78.99 82.21 70.57
Free Cash Flow per Share
(0.13) 0.03 0.06 0.14
Free Cash Flow
(30.48) 7.57 14.80 33.40
Capital Expenditures
(0.18) (0.14) (0.45) (0.58)
Other line items
Cash ROIC
(54.87%) 5.00% 9.54% 22.82%
Accounts Receivable Turnover
3.31 7.49 6.94 5.52
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.01 (0.03) (0.01) (0.01)
Research and Development Expense of Revenue
120.83% 84.96% 78.34% 75.81%
Selling, General and Administrative Expense of Revenue
12.12% 7.42% 6.72% 7.89%
Share Based Compensation of Revenue
6.04% 3.50% 2.87% 2.68%
Interest Coverage
(15.26) 6.40 16.38 18.03
Operating CF/Net income
0.60 0.47 0.41 0.88
Depreciation/Fixed assets
1.32 1.53 1.50 1.04
Capex/Depreciation
(0.02) (0.02) (0.06) (0.10)
Revenue per Share
0.65 1.03 1.06 1.00
Operating CF per Share
(0.13) 0.03 0.06 0.14
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates